CareLit · DOI-Nachweis · Pneumologie
Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS® trials in idiopathic pulmonary fibrosis (IPF)
DOI 10.1055/s-0036-1572001
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Pfeifer, G Raghu, A Wells, AG Nicholson, L Richeldi, KR Flaherty, F Le Maulf, S Stowasser, R Schlenker-Herceg, DM Hansell
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The randomized, placebo-controlled, 52-week INPULSIS® trials assessed efficacy and safety of nintedanib 150 mg bid in patients with IPF. Nintedanib significantly reduced annual rate of FVC decline vs. placebo (primary endpoint) in both trials). Key secondary endpoints were time to first acute exacerbation and change from baseline in SGRQ total score, both over 52 weeks. Methods: If a surgical lung biopsy…
Zitieren
Zitierempfehlung
M Pfeifer, G Raghu, A Wells, AG Nicholson, L Richeldi, KR Flaherty, F Le Maulf, S Stowasser, R Schlenker-Herceg, DM Hansell (2016) Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS® trials in idiopathic pulmonary fibrosis (IPF). Pneumologie (02). https://doi.org/10.1055/s-0036-1572001
Mit CareLit weiterarbeiten